EFfCI is delighted to announce the launch of a new practical training course by PCS360, developed in partnership with CEPRA and ProtoQSAR: “Alternative Methods & In Silico Tools for Ingredients Cosmetic Safety.”
The course responds to a growing demand within the cosmetics industry for professionals capable of confidently evaluating chemical compound safety using cutting-edge computational approaches. In silico models represent a transformative shift in toxicology, offering a pathway to reduce animal testing, lower resource costs, and accelerate development timelines, all while ensuring rigorous compliance with European regulatory frameworks.
Over three intensive sessions (October 27, 29, and November 3), each lasting 1.5 hours, participants will gain hands-on experience with industry-standard computational tools including QSARToolbox (QT), Toxtree, and ProtoPRED®. The curriculum is structured around three core pillars: understanding the regulatory framework for alternative methods, mastering practical toxicological prediction through QSAR and read-across techniques, and grasping the fundamentals of computational chemistry and its applications.
The course is designed for regulatory affairs specialists, product developers, R&D professionals, and compliance teams, anyone responsible for ingredient safety assessments. No prior knowledge of computational chemistry is required. Participants will receive a certificate of participation upon completion.
Who are the partners?
CEPRA specializes in comprehensive safety assessments and regulatory services, ensuring full compliance across the European market. ProtoQSAR is a computational chemistry leader focused on developing and optimizing active compounds across diverse sectors. Together with PCS360, they bring unparalleled expertise to this practical program.
Special offer for EFfCI Members: beyond Early Bird pricing, EFfCI members will benefit from an exclusive member discount on course registration.
Registration opens in late August. For more details and to stay updated, follow our LinkedIn page.
